Sustiva

Country: European Union

Language: Slovak

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

efavirenz

Available from:

Bristol-Myers Squibb Pharma EEIG

ATC code:

J05AG03

INN (International Name):

efavirenz

Therapeutic group:

Antivirotiká na systémové použitie

Therapeutic area:

HIV infekcie

Therapeutic indications:

Sustiva je indikovaná v antivírusovej kombinovanej liečbe dospelých, dospievajúcich a detí vo veku od troch rokov, ktoré sú infikované vírusom 1 (HIV-1) ľudskou imunitnou nedostatočnosťou. Sustiva nebol dostatočne študoval u pacientov s pokročilou HIV ochorenia, a to u pacientov s počtom CD4 < 50 buniek/mm3, alebo po poruche proteináz-inhibítor (PI)-obsahujúce režimy. Hoci krížovej rezistencie efavirenz s inhibítormi proteinázy hiv nebola preukázaná, tam sú v súčasnosti nedostatočné údaje o účinnosti následné použitie PI-založené kombinovaná liečba po zlyhaní režimy obsahujúce Sustiva.

Product summary:

Revision: 48

Authorization status:

oprávnený

Authorization date:

1999-05-28

Patient Information leaflet

                                1/1
EU ČÍSLO
VYMYSLENÝ
NÁZOV
SILA
LIEKOVÁ FORMA
CESTA
PODANIA
OBAL
EU/1/99/110/001
VEĽKOSŤ
BALENIA
Sustiva
50 mg
Kapsule, tvrdé
Orálna
fľaša (HDPE)
30 kapsúl
EU/1/99/110/002
Sustiva
100 mg
Kapsule, tvrdé
Orálna
fľaša (HDPE)
30 kapsúl
EU/1/99/110/003
Sustiva
200 mg
Kapsule, tvrdé
Orálna
fľaša (HDPE)
90 kapsúl
EU/1/99/110/004
Sustiva
200 mg
Kapsule, tvrdé
Orálna
blister (alu/PVC)
42 kapsúl
EU/1/99/110/008
Sustiva
600 mg
Filmom obalená tableta
Orálna
fľaša (HDPE)
30 tabliet
EU/1/99/110/009
Sustiva
600 mg
Filmom obalená tableta
Orálna
blister (alu)
30 tabliet
EU/1/99/110/010
Sustiva
600 mg
Filmom obalená tableta
Orálna
blister (alu)
90 tabliet
Liek s ukončenou platnosťou registrácie
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1/1
EU ČÍSLO
VYMYSLENÝ
NÁZOV
SILA
LIEKOVÁ FORMA
CESTA
PODANIA
OBAL
EU/1/99/110/001
VEĽKOSŤ
BALENIA
Sustiva
50 mg
Kapsule, tvrdé
Orálna
fľaša (HDPE)
30 kapsúl
EU/1/99/110/002
Sustiva
100 mg
Kapsule, tvrdé
Orálna
fľaša (HDPE)
30 kapsúl
EU/1/99/110/003
Sustiva
200 mg
Kapsule, tvrdé
Orálna
fľaša (HDPE)
90 kapsúl
EU/1/99/110/004
Sustiva
200 mg
Kapsule, tvrdé
Orálna
blister (alu/PVC)
42 kapsúl
EU/1/99/110/008
Sustiva
600 mg
Filmom obalená tableta
Orálna
fľaša (HDPE)
30 tabliet
EU/1/99/110/009
Sustiva
600 mg
Filmom obalená tableta
Orálna
blister (alu)
30 tabliet
EU/1/99/110/010
Sustiva
600 mg
Filmom obalená tableta
Orálna
blister (alu)
90 tabliet
Liek s ukončenou platnosťou registrácie
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 14-03-2024
Summary of Product characteristics Summary of Product characteristics Bulgarian 14-03-2024
Public Assessment Report Public Assessment Report Bulgarian 26-01-2018
Patient Information leaflet Patient Information leaflet Spanish 14-03-2024
Public Assessment Report Public Assessment Report Spanish 26-01-2018
Patient Information leaflet Patient Information leaflet Czech 14-03-2024
Public Assessment Report Public Assessment Report Czech 26-01-2018
Patient Information leaflet Patient Information leaflet Danish 14-03-2024
Public Assessment Report Public Assessment Report Danish 26-01-2018
Patient Information leaflet Patient Information leaflet German 14-03-2024
Public Assessment Report Public Assessment Report German 26-01-2018
Patient Information leaflet Patient Information leaflet Estonian 14-03-2024
Public Assessment Report Public Assessment Report Estonian 26-01-2018
Patient Information leaflet Patient Information leaflet Greek 14-03-2024
Public Assessment Report Public Assessment Report Greek 26-01-2018
Patient Information leaflet Patient Information leaflet English 14-03-2024
Public Assessment Report Public Assessment Report English 26-01-2018
Patient Information leaflet Patient Information leaflet French 14-03-2024
Public Assessment Report Public Assessment Report French 26-01-2018
Patient Information leaflet Patient Information leaflet Italian 14-03-2024
Public Assessment Report Public Assessment Report Italian 26-01-2018
Patient Information leaflet Patient Information leaflet Latvian 14-03-2024
Public Assessment Report Public Assessment Report Latvian 26-01-2018
Patient Information leaflet Patient Information leaflet Lithuanian 14-03-2024
Summary of Product characteristics Summary of Product characteristics Lithuanian 14-03-2024
Public Assessment Report Public Assessment Report Lithuanian 26-01-2018
Patient Information leaflet Patient Information leaflet Hungarian 14-03-2024
Summary of Product characteristics Summary of Product characteristics Hungarian 14-03-2024
Public Assessment Report Public Assessment Report Hungarian 26-01-2018
Patient Information leaflet Patient Information leaflet Maltese 14-03-2024
Public Assessment Report Public Assessment Report Maltese 26-01-2018
Patient Information leaflet Patient Information leaflet Dutch 14-03-2024
Public Assessment Report Public Assessment Report Dutch 26-01-2018
Patient Information leaflet Patient Information leaflet Polish 14-03-2024
Public Assessment Report Public Assessment Report Polish 26-01-2018
Patient Information leaflet Patient Information leaflet Portuguese 14-03-2024
Summary of Product characteristics Summary of Product characteristics Portuguese 14-03-2024
Public Assessment Report Public Assessment Report Portuguese 26-01-2018
Patient Information leaflet Patient Information leaflet Romanian 14-03-2024
Public Assessment Report Public Assessment Report Romanian 26-01-2018
Patient Information leaflet Patient Information leaflet Slovenian 14-03-2024
Summary of Product characteristics Summary of Product characteristics Slovenian 14-03-2024
Public Assessment Report Public Assessment Report Slovenian 26-01-2018
Patient Information leaflet Patient Information leaflet Finnish 14-03-2024
Public Assessment Report Public Assessment Report Finnish 26-01-2018
Patient Information leaflet Patient Information leaflet Swedish 14-03-2024
Public Assessment Report Public Assessment Report Swedish 26-01-2018
Patient Information leaflet Patient Information leaflet Norwegian 14-03-2024
Summary of Product characteristics Summary of Product characteristics Norwegian 14-03-2024
Patient Information leaflet Patient Information leaflet Icelandic 14-03-2024
Summary of Product characteristics Summary of Product characteristics Icelandic 14-03-2024
Patient Information leaflet Patient Information leaflet Croatian 14-03-2024
Public Assessment Report Public Assessment Report Croatian 26-01-2018

Search alerts related to this product

View documents history